Comparison of the Microarray-Based Assay, the Real-Time PCR Assay, and the Bidirectional Sequencing Method for CYP2C19 Genotyping

Cytochrome P450 2C19 (CYP2C19) is a clinically important enzyme that metabolizes a wide variety of drugs. Recently, some new genetic assays designed to identify the CYP2C19 genotype were introduced.

We compared the abilities of the microarray-based Verigene CYP2C19 Test (Nanosphere, USA) and the AccuPower Real-time PCR CYP (*2,*3,*17) assay (Bioneer, Korea) with the ability of the bidirectional sequencing method for the detection of CYP2C19 genotypes in 78 whole blood samples.

Among 78 specimens, 28 were *1/*1, 1 was *1/*17, 27 were *1/*2, 10 were *1/*3, 8 were *2/*2, 1 was *3/*3, and 3 were *2/*3. In the initial test, five samples (6.4%) in the Verigene assay and two samples (2.4%) in the AccuPower assay failed to generate definite results. All retests with both assays generated definitive results. In both assays, the results of CYP2C19 genotyping showed 100% final concordance with those obtained by the direct sequencing method.

These two assays could be useful for the identification of CYP2C19 genotypes in clinical laboratories.